With Macrilen now on the commercial table, AEZS is looking at a “leaner” future of expenses, cheers Jason McCarthy.
AEterna Zentaris Inc. (USA)(NASDAQ:AEZS) investors are busy throwing a party today following the news that tiny drug maker has sold its U.
Maxim’s Jason Kolbert bets AEZS’ oral test could set a new standard in addressing Adult Growth Hormone Deficiency (AGHD) with FDA approval now under its belt.
Investors love biotech stocks for the lottery ticket-like returns they can offer if a company strikes medical gold or wins the regulator’s bless. …
December is an exciting month for AEterna Zentaris Inc. (NASDAQ:AEZS) investors, with the upcoming PDUFA on December 30 for Macrilen (macimorelin), for the evaluation …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced that the Marketing Authorization Application (MAA) for the use of Macrilen™ (macimorelin) for the evaluation of adult …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) reported financial and operating results for the third quarter ended September 30, 2017.
Known by many as “the world’s smartest billionaire”, Jim Simons is the founder of the prestigious Renaissance Technologies fund. The fund- one of …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced today that the special committee of independent directors (the “Strategic Review Committee”) has engaged a consulting firm …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced today that it has filed a claim against the Company’s former CEO David Dodd and its former General …
